A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults

Project: Other project

Project Details

StatusActive
Effective start/end date4/1/223/31/27

Funding

  • Merck Sharp & Dohme Corporation: $233,200.32